查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869768

肾臟生物标记市场规模、份额和趋势分析报告：按生物标记、诊断技术、最终用途、地区和细分市场预测（2025-2033 年）

Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肾臟生物标记市场摘要

2024年全球肾臟生物标记市场规模估计为15.3亿美元，预计2033年将达到31.614亿美元。

预计从 2025 年到 2033 年，该市场将以 8.54% 的复合年增长率成长。肾臟疾病，特别是慢性肾臟病(CKD) 和急性肾损伤 (AKI) 的日益普遍，以及临床上迫切需要超越传统检测法的更早、更精确的检测，正在推动市场成长。

慢性肾臟病（CKD）通常在晚期之前没有症状，因此人们对能够揭示潜在疾病和早期损害的生物标记产生了浓厚的兴趣。据估计，美国约有3550万成年人患有慢性肾臟病，其中许多人对此毫不知情。在全球范围内，CKD影响约8.5亿人，约占成年人口的9%。一项2024年的研究预测，到2032年，八个主要国家将有近1.25亿人发展进行性CKD，比2022年增加25%。Astra Zeneca于2024年4月发布的IMPACT CKD建模研究预测，到2032年，八个国家高达16.5%的人口可能受到慢性肾臟病的影响，其中晚期病例将增加高达59.3%。在布宜诺斯艾利斯举行的2024年国际肾臟病学会世界肾臟病大会（WCN'24）上公布的研究结果强调了慢性肾臟病（CKD）作为日益严重的全球健康挑战及其对经济和环境的重大影响。庞大且不断增长的肾臟病患者群体，使得对更灵敏、更特异、更全面的生物标记检测的需求持续增长。此外，糖尿病和高血压等合併症以及人口老化进一步加重了肾臟负担，迫使临床医生和支付方在疾病早期阶段采用先进的生物标记（例如NGAL、KIM-1和Cystatin C ），以改善预后、治疗方法分层和后续观察。早期CKD未确诊率高（高达90%的病例可能在肾功能下降之前被漏诊），凸显了在传统指标（eGFR、肌酐）出现显着偏差之前，能够可靠预警早期损害的工具的市场潜力。

肾臟生物标记领域最具吸引力的机会之一在于新兴市场（亚洲、拉丁美洲和非洲）。这些地区高血压和糖尿病盛行率不断上升，人口老化加剧，导致肾臟疾病负担加重，但其诊断基础设施仍不完善。由于许多地区的诊断设备普及率仍然较低，因此，推广经济实惠的即时诊断生物标记平台具有巨大的成长潜力。例如，Sphingotec 与 Beckman Coulter 等公司合作，在标准临床检测平台上发布了 penKid 检测，这表明仍处于研究阶段的生物标记如何规模化应用于广泛的临床实践（请参阅关于 penKid 在中心检查室获得许可和部署的新闻）。在分散式环境中部署多重检测、低通量检测或更简单的快速检测，有助于弥合服务不足地区的诊断缺口。

与此同时，平台的多样性正在不断扩展。虽然酵素免疫分析法（ELISA）仍占据主导地位，但灵敏度更高的化学冷光免疫检测、多重检测、液相层析质谱联用（LC-MS）、微流体技术和照护现场免疫诊断设备正日益受到关注。例如，贝克曼库尔特公司在其免疫检测平台上应用PenKid检测，就展示如何将新型生物标记整合到检查室工作流程中。在研究领域，微流体和多体学平台支援新型生物标记的发现和多重检测，为生物标记公司提供增值分析、软体和解读服务提供了可能。

目录

第一章 肾臟生物标记市场：调查方法与范围

2. 肾臟生物标记市场：执行摘要

  • 市场概述
  • 细分市场简介
  • 竞争格局概览

3. 肾臟生物标记市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球基于生物标记的免疫检测市场分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析

第四章 肾臟生物标记市场：生物标记估算与趋势分析

  • 肾臟生物标记市场：生物标记变异分析
  • 试剂盒和检测
  • 试剂
  • 服务
  • 功能性生物标记
    • 血清肌酸酐
    • 血中尿素氮（BUN）
    • 估算肾丝球过滤率（eGFR）
  • 上调蛋白
    • 肾损伤分子-1 (KIM-1)
    • 嗜中性白血球明胶酶相关脂质运载蛋白（NGAL）
    • Cystatin C
    • 白细胞介素-18 (IL-18)
    • 其他的
  • 其他新型生物标记
    • 微型RNA生物标记
    • 蛋白质体/代谢体学标记物

第五章 肾臟生物标记市场：诊断技术/平台估算与趋势分析

  • 肾臟生物标记市场：诊断技术/平台差异分析
  • 酵素免疫分析法（ELISA）
  • 分子诊断
  • 免疫检测
  • 临床化学检测
  • 就地检验（POC​​T）设备
  • 其他新兴平台

6. 肾臟生物标记市场：终端用户需求预测及趋势分析

  • 肾臟生物标记市场：终端用途差异分析
  • 医院和诊所
  • 诊断实验室
  • 学术研究机构
  • 製药和生物技术公司
  • 其他的

7. 肾臟生物标记市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 新生物标誌物的推出
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市占率分析，2024 年
  • 公司热力图分析
  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • BioPorto Diagnostics A/S
    • SEKISUI Medical Co., Ltd
    • BioMerieux SA
    • SphingoTec GmbH
    • Randox Laboratories Ltd
    • Beckman Coulter Inc.
    • QIAGEN NV
    • EKF Diagnostics Holdings plc
Product Code: GVR-4-68040-764-4

Renal Biomarkers Market Summary

The global renal biomarkers market size was estimated at USD 1,530.0 million in 2024 and is expected to reach USD 3,161.4 million by 2033, growing at a CAGR of 8.54% from 2025 to 2033. The rising prevalence of kidney disease particularly chronic kidney disease (CKD) and acute kidney injury (AKI) along with the urgent clinical need for earlier and more nuanced detection beyond conventional measures.

CKD often remains asymptomatic until advanced stages, and biomarkers that can reveal subclinical pathology or early injury are of growing interest. In the U.S., an estimated 35.5 million adults have chronic kidney disease (CKD), and a significant number are unaware of their condition. Globally, CKD affects around 850 million people, which is approximately 9% of the adult population. A 2024 study projects that by 2032, nearly 125 million people across eight major countries will have advanced CKD, a 25% increase since 2022. In April 2024, AstraZeneca's IMPACT CKD modeling study projected that by 2032, as many as 16.5% of the population across eight countries could be affected by chronic kidney disease (CKD), with advanced-stage cases potentially increasing by up to 59.3%. The findings, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, underscored the escalating global health challenge posed by CKD and emphasized its significant economic and environmental consequences. The large and growing base of kidney disease patients ensures a continually rising demand for more sensitive, specific, and multiplex biomarker assays. In addition, co-morbidities such as diabetes, hypertension, and aging populations further exacerbate kidney stress, pushing clinicians and payers to adopt advanced biomarkers (e.g. NGAL, KIM-1, cystatin C) earlier in the disease continuum to improve prognostics, therapy stratification, and monitoring. The high rate of undiagnosed early CKD (sometimes up to 90 % of cases go unnoticed until functional decline) underscores the latent market potential for tools that reliably flag early damage before conventional metrics (eGFR, creatinine) deviate significantly.

One of the most compelling opportunities in the renal biomarker landscape lies in emerging markets-Asia, Latin America, Africa where rising incidence of hypertension, diabetes, and aging populations is intensifying the renal disease burden, yet diagnostic infrastructure remains underdeveloped. As diagnostics penetration is still relatively low in many of these geographies, the entry of affordable, point-of-care biomarker platforms offers a high-growth niche. For example, Sphingotec's collaborations (e.g. with Beckman Coulter) to release penKid assays on standard clinical lab platforms reflect how a biomarker originally confined to research can scale into broader clinical adoption. (See news of licensing and launch of penKid in central labs) The capacity to deploy multiplex panels, low-volume assays, or simpler rapid tests in decentralized settings could help bridge diagnostic gaps in underserved regions.

Meanwhile, platform diversity is growing enzyme-linked immunosorbent assays (ELISA) still command a significant share, but more sensitive chemiluminescent immunoassays, multiplex panels, mass spectrometry (LC-MS), microfluidics, and point-of-care immunodiagnostic devices are gaining traction. For instance, the penKid assay's adoption on Beckman Coulter immunoassay platforms exemplifies how a novel biomarker can be integrated lab workflows. In research settings, microfluidic and multi-omics platforms will support novel discovery and multiplex panels opening scope for biomarker companies to offer value-added analytics, software, and interpretation services.

Global Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

  • Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and reagents
  • Functional Biomarkers
    • Serum Creatinine
    • Blood Urea Nitrogen (BUN)
    • Estimated Glomerular Filtration Rate (eGFR)
  • Upregulated Proteins
    • Kidney Injury Molecule-1 (KIM-1)
    • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
    • Cystatin C
    • Interleukin-18 (IL-18)
    • Others
  • Other Novel Biomarkers
    • microRNA biomarkers
    • Proteomic/metabolomic markers
  • Diagnostic technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunoassays
  • Clinical Chemistry Assays
  • Point-of-Care Testing (POCT) Devices
  • Molecular Diagnostics
  • Other Emerging Platforms
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Renal Biomarkers Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Biomarkers Segment
      • 1.1.1.2. Diagnostic Technique/Platform Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Renal Biomarkers Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Renal Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising prevalence of kidney diseases:
      • 3.3.1.2. Government Initiatives and Health Awareness Programs
      • 3.3.1.3. Technological advancements in kidney diagnostics
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost of diagnostics test
      • 3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
  • 3.4. Global Biomarker-Based Immunoassays Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
    • 3.4.2. PESTEL Analysis

Chapter 4. Renal Biomarkers Market: Biomarkers Estimates & Trend Analysis

  • 4.1. Renal Biomarkers Market: Biomarkers Movement Analysis
  • 4.2. Kits and assays
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Functional Biomarkers
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Serum Creatinine
      • 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Blood Urea Nitrogen (BUN)
      • 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Estimated Glomerular Filtration Rate (eGFR)
      • 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Upregulated Proteins
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Kidney Injury Molecule-1 (KIM-1)
      • 4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
      • 4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Cystatin C
      • 4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Interleukin-18 (IL-18)
      • 4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Other Novel Biomarkers
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.2. microRNA biomarkers
      • 4.7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.3. Proteomic/metabolomic markers
      • 4.7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Renal Biomarkers Market: Diagnostic Technique/Platform Estimates & Trend Analysis

  • 5.1. Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
  • 5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Immunoassays
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Clinical Chemistry Assays
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Point-of-Care Testing (POCT) Devices
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Other Emerging Platforms
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Renal Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Renal Biomarkers Market: End Use Movement Analysis
  • 6.2. Hospitals and clinics
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pharmaceutical & Biotechnology Companies
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Renal Biomarkers Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Renal Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Biomarkers Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific Inc.
      • 8.5.1.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Biomarkers Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.2. Siemens Healthineers AG
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Biomarkers Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. BioPorto Diagnostics A/S
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Biomarkers Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. SEKISUI Medical Co., Ltd
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Biomarkers Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. BioMerieux SA
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Biomarkers Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. SphingoTec GmbH
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Biomarkers Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Randox Laboratories Ltd
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Biomarkers Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Beckman Coulter Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Biomarkers Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. QIAGEN N.V.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Biomarkers Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. EKF Diagnostics Holdings plc
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Biomarkers Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Renal Biomarkers Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 5 Global Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 6 Global Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 9 North America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 10 North America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 12 U.S. Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 13 U.S. Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 15 Canada Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 16 Canada Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 18 Mexico Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 19 Mexico Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 22 Europe Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 23 Europe Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 25 UK Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 26 UK Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 28 Germany Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 29 Germany Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 31 France Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 32 France Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 34 Italy Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 35 Italy Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 37 Spain Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 38 Spain Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 40 Sweden Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 41 Sweden Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 43 Norway Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 44 Norway Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 46 Denmark Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 47 Denmark Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 53 Japan Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 54 Japan Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 56 China Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 57 China Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 59 India Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 60 India Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 62 Australia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 63 Australia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 65 Thailand Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 66 Thailand Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 68 South Korea Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 69 South Korea Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 72 Latin America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 73 Latin America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 75 Brazil Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 76 Brazil Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 78 Argentina Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 79 Argentina Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 82 MEA Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 83 MEA Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 85 South Africa Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 86 South Africa Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 91 UAE Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 92 UAE Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global renal biomarkers market- Key market driver analysis
  • Fig. 7 Global renal biomarkers market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global renal biomarkers market - Porter's analysis
  • Fig. 10 Global renal biomarkers market - PESTEL analysis
  • Fig. 11 Global renal biomarkers market Biomarkers outlook key takeaways
  • Fig. 12 Global renal biomarkers market: Biomarkers movement analysis
  • Fig. 13 Functional Biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Serum Creatinine market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Blood Urea Nitrogen (BUN) market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Estimated Glomerular Filtration Rate (eGFR) market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Upregulated Proteins market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Kidney Injury Molecule-1 (KIM-1) market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Neutrophil Gelatinase-Associated Lipocalin (NGAL) market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Cystatin C market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Interleukin-18 (IL-18) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Other Novel Biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 microRNA biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Proteomic/metabolomic markers Global renal biomarkers market technology outlook key takeaways
  • Fig. 26 Global renal biomarkers market: diagnostic technique/platform movement analysis
  • Fig. 27 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 ELISA market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Clinical chemistry assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 POCT market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Global renal biomarkers market end use outlook key takeaways
  • Fig. 33 Global renal biomarkers market: end use movement analysis
  • Fig. 34 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Academic & Research Institutes market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Pharmaceutical & biotechnology companies market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Global Renal Biomarkers market: Regional movement analysis
  • Fig. 41 North America Renal Biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 43 Canada renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 45 Europe renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 46 UK renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 47 Germany renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 48 France renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 49 Spain renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 51 Denmark renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 56 China renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 57 India renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 61 Latin America renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 62 Brazil renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 63 Argentina renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 64 MEA renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 65 South Africa renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 66 Saudi Arabia renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 67 UAE renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 68 Kuwait renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 69 Strategy framework